2022 World Conference on Lung Cancer (ePosters)-EP16.02-004. Clinical Significance and Genomic Characteristics of CD56+ Circulating Tumor Cells in Small Cell Lung Carcinoma

EP16.02-004. Clinical Significance and Genomic Characteristics of CD56+ Circulating Tumor Cells in Small Cell Lung Carcinoma

Back to course

Pdf Summary

A study was conducted to investigate the clinical significance and genomic characteristics of CD56 circulating tumor cells (CTCs) in small cell lung carcinoma (SCLC). The aim of the study was to develop an EpCAM-independent method for isolating CD56CTCs and to analyze their genomic characteristics. <br /><br />The study found that isolating CD56CTCs using an immunofluorescence-based EpCAM-independent method was feasible in SCLC. CD56CTCs were characterized by a high mutation load and a unique mutational spectrum. They also showed distinct mutational signatures compared to tissue biopsies. CD56CTCs were found to be tumorigenic and harbored common SCLC genomic alterations, including TP53 mutations, RB1 loss, CREBBP alteration, NOTCH gene alteration, and EP300 mutations. Copy number variations observed in CD56CTCs were comparable to those reported in published genomic databases.<br /><br />The study also found that patients with extensive-stage SCLC showed a significantly higher number of CD56CTCs compared to patients with limited-stage SCLC. The mutation load in CD56CTCs decreased at relapse compared to diagnosis. The study also demonstrated the somatic evolution of CD56CTCs at relapse, which can help understand treatment resistance and develop strategies to overcome it.<br /><br />The clinical significance of CD56CTCs was highlighted, showing their potential as a biomarker for diagnosis, monitoring of disease progression, and prediction of overall survival. The study utilized a non-interventional prospective design and included patients with chemotherapy-naive SCLC who were eligible for systemic treatment.<br /><br />In conclusion, CD56CTCs in SCLC have clinical significance and distinct genomic characteristics. They have a high mutation load, unique mutational spectrum, and harbor common SCLC genomic alterations. The study provides insights into the potential use of CD56CTCs as a biomarker and their role in understanding treatment resistance in SCLC.

Asset Subtitle

Charles Ricordel

Meta Tag

Speaker Charles Ricordel

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

CD56 circulating tumor cells

small cell lung carcinoma

clinical significance

genomic characteristics

EpCAM-independent method

immunofluorescence-based

mutation load

mutational spectrum

tumorigenic

genomic alterations